Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trichloroacetic Acid SCHEMBL1331160 | 0.88 | — | — | |
| Trichloroacetic Acid SCHEMBL3220 | 0.88 | — | — | |
| Trichloroacetic Acid SCHEMBL38661501 | 0.88 | — | — | |
| Trichloroacetic Acid SCHEMBL10745837 | 0.88 | — | — | |
| Trichloroacetic Acid SCHEMBL1331955 | 0.88 | — | — | |
| Trichloroacetic Acid SCHEMBL10493657 | 0.88 | TSHR (1.00) | TSHRALDH1A1TP53CYP1A2CYP2D6 | |
| Trichloroacetic Acid SCHEMBL5311061 | 0.88 | TSHR (1.00) | TSHRALDH1A1TP53CYP1A2CYP2D6 | |
| Trichloroacetic Acid SCHEMBL10549726 | 0.86 | TSHR (0.67) | TSHRALDH1A1TP53CYP1A2 | |
| Trichloroacetic Acid SCHEMBL10358466 | 0.86 | TSHR (0.67) | TSHRALDH1A1TP53CYP1A2CYP2D6 | |
| Trichloroacetic Acid SCHEMBL11393443 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114686481-B | Interference RNA for inhibiting CFD expression and preparation method and application thereof | 北京键凯科技股份有限公司 | 2023-08-15 | — | — | CN | claimed |
| CN-106008136-A | Preparation method of 6,6,12,12-tetramethyl-6,12-dihydroindeno[1,2-b] fluorene | 李金铃 | 2016-10-12 | — | — | CN | claimed |
| CN-104628805-B | A kind of preparation method of amphipathic fat nucleic acid | 中国石油大学(华东) | 2016-06-08 | — | — | CN | claimed |
| CN-119462801-A | Photosensitive amphiphilic compound containing coumarin unit, and preparation method and application thereof | 中国石油大学(华东) | 2025-02-18 | — | — | CN | disclosed |
| WO-2024140596-A1 | SIRNA MOLECULE FOR REGULATING ACTIVITY OF XDH GENE | 大睿生物医药科技(上海)有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-113929724-B | Nucleoside compound, pharmaceutical composition and application thereof | 周雨恬 | 2024-05-31 | — | — | CN | disclosed |
| US-20240166674-A1 | PHOSPHORAMIDITE ACTIVATOR | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2024-05-23 | — | — | US | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| WO-2024093907-A1 | LIGAND FOR DELIVERING SIRNA TO EYE AND CENTRAL NERVOUS SYSTEM | 大睿生物医药科技(上海)有限公司 | 2024-05-10 | — | — | WO | disclosed |
| WO-2024093947-A1 | PRODRUG FOR DELIVERING SIRNA INTO CELL | 大睿生物医药科技(上海)有限公司 | 2024-05-10 | — | — | WO | disclosed |
| CN-116917477-B | Targeting ligands containing N-acetylgalactosamine | 大睿生物医药科技(上海)有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-0685457-A1 | GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-12-06 | — | — | EP | disclosed |
| EP-0685234-A1 | DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-12-06 | — | — | EP | disclosed |
| US-5427929-A | Enzyme pretreatment | AMGEN INC. (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0321548-A4 | NOVEL AMPHIPHILIC NUCLEIC ACID CONJUGATES | — | 1991-01-30 | — | — | EP | disclosed |
| US-4904582-A | Novel amphiphilic nucleic acid conjugates | SYNTHETIC GENETICS (US) | 1990-02-27 | — | — | US | disclosed |
| WO-1989005853-A1 | NUCLEIC ACID CHELATE CONJUGATE AS THERAPEUTIC AND DIAGNOSTIC AGENTS | SYNTHETIC GENETICS (US) | 1989-06-29 | — | — | WO | disclosed |
| EP-0321548-A1 | NOVEL AMPHIPHILIC NUCLEIC ACID CONJUGATES | SYNTHETIC GENETICS (US) | 1989-06-28 | — | — | EP | disclosed |
| WO-1988009810-A1 | NOVEL AMPHIPHILIC NUCLEIC ACID CONJUGATES | SYNTHETIC GENETICS (US) | 1988-12-15 | — | — | WO | disclosed |
| US-4701304-A | Apparatus for automated synthesis of peptides | APPLIED PROTEIN TECHNOLOGIES, INC. (US) | 1987-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166674-A1 | PHOSPHORAMIDITE ACTIVATOR | ITPA, INPP5D, INPP5B | TSHR 1564/4885ALDH1A1 3801/4885TP53 2360/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | TSHR 1056/4885ALDH1A1 4857/4885TP53 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.